Guselkumab approved in the EU for the treatment of active psoriatic arthritis

Guselkumab is a first-in-class monoclonal antibody that binds to IL-23 and inhibits its interaction with the IL23 receptor. It is approved for use in people who have had an inadequate response to or have been intolerant to prior DMARD therapy.

Source:

PharmaTimes